EyePoint (EYPT) stock rose 10% after the company reported six-month results from a phase 2 study of its drug Duravyu in the treatment of diabetic macular edema. Read more here.

The new indication adds to the 2021 approval of Susvimo (ranibizumab) for 'wet' or neovascular age-related macular ...

The World Health Organization reports that around 2.2 billion people struggle with vision problems such as near-sightedness ...

The cholesterol that’s good for your heart health might be bad for your eye health, and vice versa, a new study says ...

James analyst Dane Leone maintained a Strong Buy rating and a $19.00 price target on Ocular Therapeutix (NASDAQ:OCUL), aligning with the broader analyst consensus. According to InvestingPro data, ...

A small percentage of patients taking GLP-1 medications have experienced vision problems, but a direct causal link with the ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema ...

Good (HDL) cholesterol may raise glaucoma risk, while ‘bad’ (LDL) cholesterol could lower the risk of vision loss from ...

Good' (HDL) cholesterol, usually considered to be beneficial for health, may be linked to a heightened risk of the serious ...

Drug distributor Cencora raised its fiscal 2025 profit forecast on Wednesday, driven by robust demand for expensive specialty medicines.

Introduction: The global smart contact lenses market is experiencing an exciting transformation, fueled by cutting-edge ...